Pain Management in Response to Exparel vs. Standard Bupivicaine
NCT02499159
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Pain
Interventions
DRUG:
Liposomal Bupivicaine
DRUG:
0.25% standard bupivicaine
Sponsor
Inova Health Care Services
Collaborators
[object Object]